Investigation into Lipid Management in Acute Coronary Syndrome Patients from the EXPLORE-J Study.
Acute coronary syndrome
Cardiovascular risk
Japan
Low-density lipoprotein cholesterol
Journal
Journal of atherosclerosis and thrombosis
ISSN: 1880-3873
Titre abrégé: J Atheroscler Thromb
Pays: Japan
ID NLM: 9506298
Informations de publication
Date de publication:
01 Jun 2019
01 Jun 2019
Historique:
pubmed:
7
12
2018
medline:
4
12
2019
entrez:
7
12
2018
Statut:
ppublish
Résumé
The EXPLORE-J study aimed to assess lipid management in patients hospitalized for acute coronary syndrome (ACS) and their cardiovascular risk despite undergoing standard therapy. Here, we focused on background characteristics of patients in the EXPLORE-J study to elucidate the current lipid-lowering therapy and its issues in Japan. In this multicenter, prospective, observational study (UMIN000018946), consecutive Japanese ACS patients who required hospitalization were registered between April 2015 and August 2016. Background and lipid profile data collected within 14 days of hospitalization were analyzed according to risk factors such as diabetes mellitus status. In total, 1944 patients were analyzed (80.3% male). The mean and standard deviation (SD) age and body mass index of all patients were 66.0 years (SD: 12.2) and 24.24 kg/m Many patients were not meeting Japanese LDL-C target levels at the time of ACS, and a large proportion of patients meeting target levels developed ACS; therefore, more stringent management and further evaluation of the target LDL-C levels is warranted in high-risk patients and those with previous history of CAD.
Identifiants
pubmed: 30518728
doi: 10.5551/jat.45583
pmc: PMC6545456
doi:
Substances chimiques
Anticholesteremic Agents
0
Biomarkers
0
Cholesterol, LDL
0
Lipids
0
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
559-572Références
Circulation. 2004 Jul 13;110(2):227-39
pubmed: 15249516
Lancet. 2005 Oct 8;366(9493):1267-78
pubmed: 16214597
JAMA. 2008 Apr 9;299(14):1678-89
pubmed: 18398080
J Am Coll Cardiol. 2008 Jul 1;52(1):71-9
pubmed: 18582638
Cardiovasc Drugs Ther. 2010 Feb;24(1):77-83
pubmed: 20352313
J Atheroscler Thromb. 2011;18(2):83-8
pubmed: 21307610
Eur Heart J. 2011 Jul;32(14):1769-818
pubmed: 21712404
EPMA J. 2011 Mar;2(1):49-57
pubmed: 23199126
PLoS One. 2013 Sep 06;8(9):e74699
pubmed: 24040326
Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45
pubmed: 24222016
J Atheroscler Thromb. 2014;21(8):784-98
pubmed: 24671110
Am J Epidemiol. 2014 Jun 1;179(11):1293-300
pubmed: 24743066
J Atheroscler Thromb. 2015;22(12):1287-304
pubmed: 26289083
JAMA. 2016 Sep 27;316(12):1289-97
pubmed: 27673306
BMJ Open. 2017 Jul 2;7(6):e014427
pubmed: 28674132
Cardiovasc Diabetol. 2017 Oct 2;16(1):123
pubmed: 28969633
J Atheroscler Thromb. 2018 Apr 1;25(4):308-322
pubmed: 29238010
J Atheroscler Thromb. 2018 Jul 1;25(7):606-620
pubmed: 29321397
J Atheroscler Thromb. 2018 Apr 1;25(4):304-305
pubmed: 29467342
J Atheroscler Thromb. 2018 Sep 1;25(9):846-984
pubmed: 30135334